Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
NASDAQ:ENTX
Price:
2.62 USD
4.38%
Market Closed
Updated:
May 16, 2024
Entera Bio Ltd
Income from Continuing Operations
|
Entera Bio Ltd
Income from Continuing Operations Peer Comparison
Comparables:
CLGN
KMDA
B
BLRX
URGN
B
BONS
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Income from Continuing Operations
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Income from Continuing Operations
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Income from Continuing Operations
$8.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
34%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Income from Continuing Operations
-$60.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-14%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Income from Continuing Operations
-$102.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Income from Continuing Operations
-₪31m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
See Also
What is Entera Bio Ltd's Income from Continuing Operations?
Income from Continuing Operations
-8.9m
USD
-8.9m
USD
Based on the financial report for Dec 31, 2023, Entera Bio Ltd's Income from Continuing Operations amounts to -8.9m USD.
What is Entera Bio Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
3%
3%
Over the last year, the Income from Continuing Operations growth was 32%. The average annual Income from Continuing Operations growth rates for Entera Bio Ltd have been 7% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
